Nascent Medical Therapies for Abdominal Aneurysms
Neal R. Barshes, MD, MPH

Efforts to identify medical therapies that halt the growth of aneurysms have been underway for at least 20 years. Two studies published in this issue of the Journal of the American Heart Association (JAHA) give us some idea of how medical therapy will more often be considered a core component of the management of aortic abdominal aneurysms.

First, a meta-analysis by Al-Omran and colleagues identifies an association between statin medications and significantly slower aneurysm growth rates, fewer aneurysm ruptures, and improved perioperative survival. The results are compelling and suggest that statin therapy may be beneficial for patients with abdominal aneurysms (including larger aneurysms) who do not otherwise meet indications for statin therapy indications. With the favorable safety profile and the low cost of statins, it may be reasonable for clinicians to initiate high-intensity statin therapy for such patients, even without a confirmation from a randomized controlled trial. Perhaps even more important, clinicians should ensure statin therapy has been prescribed for all patients with abdominal aneurysm who already do meet typical indications. Several recent series report that only 60% to 70% of patients with peripheral artery disease receive statin therapy, and there is no reason to expect that the rate would be any higher in patients with abdominal aneurysms.

Matrix metalloproteinases have been implicated in the pathogenesis of abdominal aneurysms through degradation of aortic wall elastin and collagen. Preclinical work had suggested the lipid-lowering agent fenofibrate downregulated matrix metalloproteinases. A small randomized trial, reported by Golledge and colleagues in this issue of JAHA, failed to demonstrate fenofibrate therapy significantly slowing growth of abdominal aneurysms. Aneurysm growth is typically a few millimeters per year, so it may not be surprising that no significant differences were found at 24 weeks. Follow-up of their cohort beyond 24 weeks may show a slowing of the growth rate not yet appreciated by these investigators.

Antibiotic use may merit more attention from clinicians managing abdominal aneurysms. Doxycycline has been investigated as a molecule to inhibit matrix metalloproteinase activity since the 1990s, and pooled results from several trials on doxycycline suggest this antibiotic may slow aneurysm growth. In contrast to doxycycline, fluoroquinolones may potentiate aneurysm growth and rupture. Preclinical work from LeMaire and colleagues, demonstrating that increased matrix metalloproteinase activity is one of several effects of ciprofloxacin, provides an important piece of evidence that makes the association of ciprofloxacin and aneurysm rupture more compelling.

Population-level and preclinical studies suggest metformin may also slow aneurysm growth. Randomized trials of metformin therapy have been performed on nondiabetic populations (including, for example, nondiabetic subjects with coronary artery disease), so further studies of metformin as a potential medical therapy for abdominal aneurysms may be forthcoming.

While searching for medical therapies, we should not forget the impact of lifestyle on aneurysms. The aneurysm mortality incidence rate in the United States closely mirrors per capita cigarette consumption rates, and it is encouraging that rates of both are decreasing sharply. Clinicians must discuss tobacco use at each clinic visit, emphasize the health benefits of smoking cessation, and provide support to achieve complete abstinence (including free resources from smoke-free.gov and 800-QUIT-NOW). We now know, from the work of Dalman and colleagues, that although exercise therapy does...
not halt growth, it is perfectly safe for people with aneurysms to exercise regularly.19

In summary, experimental studies evaluating medical therapies for abdominal aortic aneurysms suggest benefit from statins, doxycycline, and possibly metformin. Fluoroquinolones and tobacco seem harmful. Exercise does not adversely affect abdominal aneurysms and should be encouraged for the countless other benefits provided.

Disclosures
None.

References
1. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998;28:1082–1093.
2. Salata K, Syed M, Hussain M, de Mestral C, Greco E, Mamdani M, Tu JV, Forbes TL, Bhatt D, Verma S, Al-Omran M. Statins reduce abdominal aneurysm growth, rupture, and perioperative mortality: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7:e008657. DOI: 10.1161/JAHA.118.008657.
3. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lockstein R, Misra S, Muneebee L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e686–e725.
4. Gray C, Goodman P, Cullen P, Badger SA, O’Malley K, O’Donohoe MK, McDonnell CO. Screening for peripheral arterial disease and carotid artery disease in patients with abdominal aortic aneurysm. Angiology. 2016;67:346–349.
5. Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Arterioscler Thromb Vasc Biol. 2010;30:1075–1077.
6. Stone NJ, Robinson JG, Lichtenstein AH, Bailey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF, Edelman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kostis JB, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Tomassili GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–S45.
7. De Martino RR, Hoel AW, Beck AW, Eldrup-Jorgensen J, Hallett JW, Upchurch GR, Cronenwett JL, Goodney PP; Vascular Quality Initiative. Participation in the Vascular Quality Initiative is associated with improved perioperative medication use, which is associated with longer patient survival. J Vasc Surg. 2015;61:1010–1019.
8. Meltzer AJ, Sedrakyan A, Connolly PH, Ellozy S, Schneider DB; Vascular Study Group of Greater. Risk factors for suboptimal utilization of statins and antiplatelet therapy in patients undergoing revascularization for symptomatic peripheral arterial disease. Ann Vasc Surg. 2018;46:234–240.
9. Halle TR, Baranroch-Gampel J, Teodeorescu VJ, Rajani RR. Surgical intervention for peripheral artery disease does not improve patient compliance with recommended medical therapy. Ann Vasc Surg. 2018;46:104–111.
10. Pinchbeck JL, Moxon JV, Rowbotham SE, Bourke M, Lazzaroni S, Morton SK, Matthews EQ, Hendy K, Jones RE, Bourke B, Jaeggi R, Favot D, Quigley F, Jenkins JS, Reid CM, Velu R, Golledge J. A randomized placebo-controlled trial assessing the effect of 24 weeks fenofibrate therapy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME-2 trial. J Am Heart Assoc. 2018;7:e009866. DOI: 10.1161/JAHA.118.009866.
11. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of atherosymal degeneration in an elastase-implanted rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336–346.
12. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev. 2012;5:CD009536.
13. Ra, Zhang S, Luo W, Ren P, Azares AR, Wang Y, Zhang C, Coselli JS, Shen YH. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg. 2018;11:e181804.
14. Lee C-C, Lee M-TG, Chen Y-S, Lee S-H, Chen Y-S, Chen S-C, Chang S-C. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175:1839–1847.
15. Fujimura N, Xiong J, Kettler EB, Xuan H, Glover KJ, Mell MW, Xu B, Dalman RL. Metformin treatment status and abdominal aortic aneurysm disease progression. J Vasc Surg. 2016;64:54–58.e8.
16. Golledge J, Moxon J, Pinchbeck J, Anderson G, Rowbotham S, Jenkins J, Bourke M, Bourke B, Dear A, Buckenham T, Jones R, Norman PE. Association between metformin prescription and growth rates of abdominal aortic aneurysms. Br J Surg. 2017;104:1486–1493.
17. Preiss D, Lloyd SM, Ford I, McMurray JJ, Holman RR, Welsh P, Fisher M, Packard CJ, Sattar N. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2:116–124.
18. Lederle FA. The rise and fall of abdominal aortic aneurysm. Circulation. 2011;124:1097–1099.
19. Myers J, McElrath M, Jaffe A, Smith K, Fonda H, Vu A, Hill B, Dalman R. A randomized trial of exercise training in abdominal aortic aneurysm disease. Med Sci Sports Exerc. 2014;46:2–9.

Key Words: Editorials • aneurysm • fluoroquinolone • metformin • statin